DUTREBIS
LOE ApproachingNDAORALTABLET
Approved
Feb 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUTREBIS is an oral tablet NDA approved by Merck & Co. in February 2015. Specific mechanism of action and indications are not publicly detailed in available data. The drug is currently approaching loss of exclusivity (LOE) with patent protection expiring in 2029.
LOE Approaching2.8 years to LOE
Product is in advanced stages of market maturity with approximately 2.9 years of patent protection remaining; commercial teams should anticipate transition to defense and generic preparation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on DUTREBIS at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.